| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 07, 2022 |
Director
Trans History: 18
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 44,470 | $0.51 | 58,364 |
| Aug 15, 2022 |
Director
Trans History: 11
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | $0.38 | 20,000 |
| Apr 06, 2020 |
Director
Trans History: 14
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 45,000 | $0.32 | 64,500 |
| Apr 06, 2020 |
Director
Trans History: 14
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 45,000 | $0.01 | 45,000 |
| Oct 23, 2019 |
Director
Trans History: 14
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 9,500 | $0.01 | 9,500 |
| Mar 05, 2024 |
Director, PRESIDENT AND CEO
Trans History: 29
|
Director, PRESIDENT AND CEO | Form 4 | Other acquisition or disposition | -- | -- | 502 |
| Sep 20, 2023 |
Chief Financial Officer
Trans History: 2
|
Chief Financial Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 144,794 |
| Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 |
| Sep 18, 2023 |
Chief Financial Officer
Trans History: 2
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 106,000 | -- | 106,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.